Paradigm Biopharmaceuticals (ASX:PAR) Gross Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Paradigm Biopharmaceuticals's Gross Profit for the six months ended in Dec. 2023 was A$0.00 Mil. Paradigm Biopharmaceuticals's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Paradigm Biopharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Paradigm Biopharmaceuticals's Gross Margin % or its related term are showing as below:

ASX:PAR' s Gross Margin % Range Over the Past 10 Years
Min: -376.19 Med: -82.28 Max: 73.81
Current: 73.81

During the past 8 years, the highest Gross Margin % of Paradigm Biopharmaceuticals was 73.81%. The lowest was -376.19%. And the median was -82.28%.

ASX:PAR's Gross Margin % is ranked better than
67.76% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs ASX:PAR: 73.81

Paradigm Biopharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Paradigm Biopharmaceuticals was 0.00% per year.

Paradigm Biopharmaceuticals Gross Margin % Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Gross Margin % Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross Margin %

Get a 7-Day Free Trial

-376.19

-82.28

59.57

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial												-55.56	-114.71	-60.00	73.81	-

Competitive Comparison of Paradigm Biopharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Gross Margin % falls into.

Paradigm Biopharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Paradigm Biopharmaceuticals's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )	=	Gross Profit (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	0	/	0.047
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.047 - 0.019)	/	0.047
	=	59.57 %

Paradigm Biopharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Paradigm Biopharmaceuticals (ASX:PAR) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Paradigm Biopharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Paradigm Biopharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).